Pharmacist's interview with type 2 diabetes: Development of a follow-up form - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Annales Pharmaceutiques Françaises Année : 2017

Pharmacist's interview with type 2 diabetes: Development of a follow-up form

Résumé

ObjectivesType 2 diabetes is a major public health concern because of its prevalence, the severity of complications and the financial implications. Compliance and patient's autonomy in medications intake play key roles in the success of treatment. Pharmacists’ interviews ensure an optimized and individual follow-up. Type 2 diabetes is not one of the targeted diseases to perform pharmacists’ interviews on under Health Insurance. We thus judged useful to contribute to their development.MethodsWe applied a cross-disciplinary methodological process in order to define the specifications of the follow-up form useful to conduct the pharmacist's interview 1 by focusing on the identification of a non-compliance and its origins. A feasibility study was carried out in order to check its workability to the pharmacy practice.ResultsThe follow-up form, associated with a pharmacist practical guide, includes 3 parts: (1) General informations, (2) Survey establishing patient's knowledge, (3) Summary including a level of knowledge assessment grid. Outcomes provide a long but appropriate-felt duration, few difficulties to conduct the interview and a proven usefulness in 90% of all cases that make the follow-up form suitable to the pharmacy practice.ConclusionsThis tool could serve as a model for the pharmacist to conduct his future interviews for the type 2 diabetes patients, thus improving patient care, together with other health professionals.
Fichier non déposé

Dates et versions

hal-01649567 , version 1 (27-11-2017)

Identifiants

Citer

P. Garcia Santos, L. Bernard, S. Bedhomme, S. Blum, M. Gravelin, et al.. Pharmacist's interview with type 2 diabetes: Development of a follow-up form. Annales Pharmaceutiques Françaises, 2017, 75 (5), pp.385 - 397. ⟨10.1016/j.pharma.2017.03.001⟩. ⟨hal-01649567⟩
125 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More